Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3HN3U)

Drug Name
Afimetoran Drug Info
Synonyms
Afimetoran; 2171019-55-7; Afimetoran [USAN]; LXP7MZL0VF; BMS-986256; UNII-LXP7MZL0VF; WHO 11516; BMS 986256; 2-(4-(2-(7,8-Dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)acetamide; 1-Piperidineacetamide, 4-(2-(7,8-dimethyl(1,2,4)triazolo(1,5-a)pyridin-6-yl)-3- (1-methylethyl)-1H-indol-5-yl)-; 2-(4-(2-(7,8-dimethyl(1,2,4)triazolo(1,5-a)pyridin-6-yl)-3-(propan-2-yl)-1H-indol-5-yl)piperidin-1-yl)acetamide; AFIMETORAN [INN]; CHEMBL4650329; SCHEMBL19761011; BDBM273241; EX-A6745; US10071079, Example 15; AKOS040757385; MS-28017; HY-139567; CS-0213544; 1-PIPERIDINEACETAMIDE, 4-(2-(7,8-DIMETHYL(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-3-(1-METHYLETHYL)-1H-INDOL-5-YL)-; 2-(4-(2-(7,8-DIMETHYL(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-3-(PROPAN-2-YL)-1H-INDOL- 5-YL)PIPERIDIN-1-YL)ACETAMIDE; 2-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl) piperidin-1-yl)acetamide; 2-[4-[2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-propan-2-yl-1H-indol-5-yl]piperidin-1-yl]acetamide
Indication
Disease Entry ICD 11 Status REF
Systemic lupus erythematosus 4A40.0 Phase 2 [1]
Cross-matching ID
PubChem CID
132271862
TTD Drug ID
DM3HN3U

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Toll-like receptor 7 (TLR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [3]
Hydroxychloroquine DMSIVND Chronic renal failure GB61.Z Approved [4]
ANA773 DMSC8YW Hepatitis C virus infection 1E51.1 Phase 2a [5]
GS-9620 DMG5C8D Hepatitis B virus infection 1E51.0 Phase 2 [6]
IMO-3100 DMM549D Psoriasis vulgaris EA90 Phase 2 [7]
Resiquimod DML6XSP Actinic keratosis EK90.0 Phase 2 [8]
LOXORIBINE DMIV9ZE Immune System disease 4A01-4B41 Phase 2 [9]
GSK2245035 DMBWPZJ Asthma CA23 Phase 2 [10]
AZD-8848 DM0M7QW Allergic rhinitis CA08.0 Phase 2 [11]
Isatoribine DMHOJ8W Hepatitis C virus infection 1E51.1 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Toll-like receptor 8 (TLR8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Resiquimod DML6XSP Actinic keratosis EK90.0 Phase 2 [8]
Selgantolimod DMST4OR Hepatitis B 1E51 Phase 2 [13]
NKTR-262 DMYR8LF Solid tumour/cancer 2A00-2F9Z Phase 1/2 [14]
CPG 52364 DMVDYTG Systemic lupus erythematosus 4A40.0 Phase 1 [15]
CV8102 DMYD37G Melanoma 2C30 Phase 1 [16]
MEDI9197 DM0J7UR Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
SBT6050 DMHBD3T Solid tumour/cancer 2A00-2F9Z Phase 1 [18]
VTX-1463 DM4ZIRK Allergic rhinitis CA08.0 Phase 1 [19]
DN1508052 DM0JT9C Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
GSK5251738 DM8Y6DR Hepatitis B 1E51 Phase 1 [21]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 7 (TLR7) TTRJ1K4 TLR7_HUMAN Inhibitor [2]
Toll-like receptor 8 (TLR8) TT8CWFK TLR8_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04895696) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Systemic Lupus Erythematosus. U.S.National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
3 Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
4 TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
5 Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
6 Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
7 Company report (Iderapharma)
8 TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
9 The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
10 Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
11 Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
12 Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
13 Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
14 Clinical pipeline report, company report or official report of Nektar Therapeutics.
15 Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
16 Clinical pipeline report, company report or official report of CureVac.
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 Clinical pipeline report, company report or official report of Silverback Therapeutics.
19 VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
20 Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.
21 Clinical pipeline report, company report or official report of GlaxoSmithKline